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Psoriasis is a chronic, recurrent, inﬂammatory, and hyperproliferative disease. Recently there have been studies regarding increases
in the levels of NO in inﬂammatory dermatoses including psoriasis. In this study, 22 patients with psoriasis were scored with PASI
(psoriasisareaandseverityindex)andthelevelsofserumnitrite-nitratewereevaluatedbeforeandaftertherapywithmethotrexate
(Mtx). The results were compared with age- and sex-matched healthy volunteers. The relation of the results with the clinical
severity and the cumulative Mtx dose were also evaluated. The serum levels of nitrite-nitrate of the psoriatic patients with active
lesions were found to be signiﬁcantly higher than the levels of the healthy volunteers and the patients after therapy. The elevated
nitrite-nitrate serum levels in the inﬂammatory period may suggest the possible role of this mediator in the etiopathogenesis of
psoriasis and the potential future use of NO inhibitors in the treatment of psoriasis.
Copyright © 2006 Nilgun Solak Tekin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Psoriasis is a common chronic skin disease mediated by
cellular immune mechanisms and characterized by an in-
tense neutrophile cell inﬁltrate and proliferative activation
of epidermal keratinocytes. It is generally assumed that un-
balanced immune responses contribute to the pathogenesis
[1, 2]. The exact sequence of events, as well as the molecu-
lar mediators that lead to hyperproliferative responses, is yet
to be deﬁned. As a potent regulator of keratinocyte growth
and diﬀerentiation, the multifunctional signaling molecule
nitric oxide (NO) has been considered to be a strong candi-
date in the pathogenesis of psoriasis [3–5]. This heat-labile
and unstable compound is synthesized in endothelial cells
as well as neurons by constitutive NOS synthase (cNOS),
while inducible NO synthase (iNOS) is found in leucocytes,
macrophages, and mesengial cells. A small amount of NO
produced by cNOS in endothelium is responsible for the
relaxation of adjacent smooth muscles and prevents adhe-
sion of platelets and leucocytes to the endothelium. This
is the anti-inﬂammatory eﬀect of NO [6]. However, when
produced in large amounts NO can destroy tissues and im-
pair immune response. High levels are demonstrated in im-
munological disorders like systemic lupus erythematosus or
rheumatoid arthritis. Hence, inhibition of iNOS is an eﬀec-
tive modality of treatment in these conditions [7]. The pro-
ductionofnitricoxideis ∼10-foldhigherinnonlesionalskin
of psoriatics and ∼10-fold higher again in the plaques them-
selves [8].
Although studies showed the elevated NO levels in psori-
atic tissue samples, as far as we know there are very few stud-
ies exploring serum NO levels in psoriatic patients [9–14].
Methotrexate (Mtx) is an analogue of folic acid and an
antiproliferative agent through its competitive binding to di-
hydrofolate reductase. Although the eﬀectiveness of Mtx in
the treatment of psoriasis is very well established, the mecha-
nism of action is poorly understood [15, 16]. There are some
studies suggesting that Mtx decreases the NO levels in psori-
asis [13].
In our study, the role of NO in the pathogenesis of pso-
riatic inﬂammation, the relation between NO and PASI and
the eﬀect of methotrexate on NO in psoriatic patients serum
were investigated.
PATIENTS AND METHODS
Twenty-two patients (sixteen males and six females) with
clinically active psoriasis vulgaris and twenty-one healthy2 Mediators of Inﬂammation
controls (fourteen males and seven females) were selected
from the outpatient clinic of Department of Dermatology,
Gazi University Hospital. Active psoriasis was deﬁned as
plaquesincreasinginsizeandnumberatthetimeofresearch.
The ages of patients and controls ranged from 18 to 59 years
(mean 35.00±11.8 0 )a n d1 7t o4 6y e a r s( m e a n2 9 .48±7.54),
respectively. The groups were similar in most demographic
characteristics.Thedurationofpsoriasis(years)rangedfrom
1t o2 0( m e a n8 .80 ± 6.52). Informed consent was obtained
afterthestudyhadbeenfullyexplained.Allpatientshadclin-
ical and histopathological diagnosis for chronic plaque-type
psoriasis.
The assessment of the severity and extent of disease was
donebyPASIscore.Theinclusioncriterionwasanactivedis-
ease which had PASI score above [16]. The exclusion crite-
ria were coexisting inﬂammatory skin disease, topical ther-
apy within 4 weeks, systemic therapy or photochemotherapy
within 3 months. Pregnant or lactating women and patients
with systemic disease were also excluded.
Five ml of venous blood was collected using vacutainer
tubes with ethylenediaminetetraacetic acid (EDTA) as anti-
coagulant and centrifuged at 1000g within 30min of col-
lection. Serum samples of patient and control groups were
stored at −70◦C until they were assayed in one run.
T h ed o s eo fm e t h o t r e x a t ew a s2 0m gp e rw e e k( g i v e ni n
three divided doses with a 12-hour interval between doses).
Clinical response was usually evident in 7–14 days, but max-
imal response was taken between 4th–8th weeks. As soon
as acceptable control was achieved, the dosage was lowered
or the interval between doses was extended. Patients who
weretreatedwithmethotrexateunderwentthefollowinglab-
oratory tests every two weeks during the ﬁrst month and
monthly thereafter, a complete blood count and assays of
electrolytes, serum creatinine, blood urea nitrogen, aspartate
aminotransferase, alanine aminotransferase, alkaline phos-
phatase, and bilirubine.
Serum samples were obtained before Mtx therapy, and
at the time the lesions completely disappeared (PASI = 0).
ThecumulativeMtxdosewascalculatedwhenPASI = 0.The
length of the therapy and the cumulative Mtx dose were dif-
ferent for each psoriasis patient.
The results were compared with 21 healthy volunteers.
The relation of the results with the clinical severity and the
cumulative Mtx dose was also evaluated. As NO is an unsta-
ble molecule, it is rapidly converted to nitrates and nitrites in
the body; hence their concentration is parallel to NO levels.
Nitritedetermination
Nitrite was measured by using a Griess reaction [17]. The
results were given as μmol/L.
Nitratedetermination
Nitrate was measured using the enzymatic one-step assay
with nitrate reductase [18]. This method is based on the re-
duction of nitrate to nitrite by nitrate reductase in the pres-
ence of β-NADPH. Tubes containing 250μl of 100mmol/l
potassium phosphate buﬀer (pH 7.5), 50μl of 12mmol/l β-
NADPH, and 100μl sample were equilibrated at 25◦C. To
start the enzymatic reaction, 40μl of 500U/l nitrate reduc-
tasewasadded.Thesampleswereincubatedfor45mininthe
dark. The oxidation of β-NADPH was monitored in terms of
the decrease in absorbency at 340nm. The method of stan-
dard addition was used to minimize the eﬀect of interfering
substances from the serum. The results are given as micro-
moles per liter. Samples with internal standard, and serum
and reagent blanks were also analyzed.
Statisticalanalysis
To compare diﬀerences in nitrite-nitrate levels, results (be-
fore and after therapy, and nonpsoriatic patients) were as-
sessed using Wilcoxons test and Mann-Whitney U test. Cor-
relations between PASI score, cumulative MTX dose, and
nitrite-nitrate serum levels were analyzed with the Spearman
rho correlation. SPSSWindows release11.5(SPSSInc.,USA)
w a su s e d .A l lv a l u e sw e r ee x p r e s s e da sm e a n± standard of
means (SEM) unless stated otherwise. Statistical signiﬁcance
level was set to 0.05 for all calculations.
RESULTS
All patients were successfully treated with Mtx according to
the schedule. The mean PASI score was 36.10 ± 1.87 at the
baseline of therapy and the mean cumulative Mtx dose was
235 ± 22.34mg at the time the lesions completely disappear
(PASI = 0). The patients tolerated the therapy well. And
there were no signiﬁcant adverse eﬀects. The mean baseline
valuesofnitrite-nitrateconcentrationsintheseraofpsoriasis
patients were 27.98±7.40μmol/L and 85.28±10.45μmol/L,
whilethatintheseraofpatientsaftertreatmentwere10.028±
2.05μmol/L and 39.60 ± 7.88μmol/L. The mean values of
serum nitrite-nitrate concentrations of healthy controls were
2.98 ± 0.77μmol/L and 19.08 ±5.0μmol/L.
Serum levels of nitrite-nitrate were both signiﬁcantly
higher in patients with psoriasis before treatment than in
controls and patients after treatment (P<. 05) (Figures 1
and 2). No correlation was found between PASI score and
serum nitrite-nitrate levels before therapy in the patients
(r =− 0.085 and p = 0.708 for nitrite; r = 0.368 and p =
0.092 for nitrate).
WefoundnocorrelationbetweencumulativeMtxdosage
serum nitrite-nitrate levels in patients after treatment. (r =
−0.262 and p = 0.239 for nitrite; r =− 0.094 and p = 0.677
for nitrate).
DISCUSSION
In recent years, the clonality of lymphocytes in psoriatic le-
sions and the increased cytokine release in that region are
well established. Cytokines, such as IFNγ,T N F α, IL-8, IL-1,
and IL-6, are most important ones [9, 19, 20]. An important
marker of inﬂammation NO is one of these mediators. NO is
a labile mediator that can be detected in high levels in the ex-
istenceofthesecytokines.NOisreleasedcontinuouslyinlowNilgun Solak Tekin et al 3
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Figure1:Serumlevelsofnitriteweresigniﬁcantlyhigherinpatients
with psoriasis before treatment than in controls and patients after
treatment (P<. 05).
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Figure 2: Serum levels of nitrate were signiﬁcantly higher in pa-
tients with psoriasis before treatment than in controls and patients
after treatment (P<. 05).
concentration while for high concentrations a stimulation is
needed [21, 22]. It has been shown that NO is increased in a
number of skin disorders with a stimulation. In the lesional
tissue samples of contact dermatitis, atopic dermatitis, sys-
temic lupus erythematosus, and psoriasis, NO is signiﬁcantly
higher than controls [23–26]. Increased NO synthesis sug-
gests a role for the pathogenesis of psoriasis. NO may trig-
ger the psoriatic disease process at least partly through in-
crement of the release and actions of calcitonin gene-related
peptide and substance P, which are considered to play im-
portant roles in the pathomechanism of psoriasis by induc-
ing the production of adhesion molecules, keratinocyte hy-
perproliferation,mastcelldegranulation,vasodilatation,and
chemotaxis of neutrophils [27]. Cals-Gierson and Ormerod
have suggested that NO stimulates epithelial cells to release
chemokines and growth mediators which appear to be im-
portant for keratinocyte proliferation and angiogenesis [28].
In previous studies, NO levels have been measured in tis-
sue samples from psoriasis patients [8, 9, 11, 13, 14]. How-
ever, we could ﬁnd very few similar research investigating ni-
trite and nitrate levels in blood samples of psoriatic patients
[10, 12]. And there has been no study showing the eﬀects of
the Mtx upon NO levels in human sera. NO is a highly reac-
tive free radical with a very short half life. The labile nature
of NO makes it impossible to analyze serum and tissue levels.
The nonfunctional metabolites of NO; nitrite and nitrate are
helpfultosearchtheamountofNO.Nitritelevelsareconsid-
ered the marker of NO in tissue and other body ﬂuids. It is
important to study nitrate levels as the nitrite is reduced into
nitrate by oxyhemoglobine, in blood [11–13, 17].
Orem et al studied NO levels in 17 patients of psoriasis
duringactiveandinactivephases[12].Inthatstudythebase-
line serum nitrite-nitrate levels of severe psoriatic patients
(the mean PASI score was 16.5) compared with after topi-
cal treatment results and found only the nitrite levels are sig-
niﬁcantly diﬀerent. They observed no signiﬁcant diﬀerence
for nitrate. They also demonstrated a positive correlation be-
tween nitrite levels and PASI scores. There was no healthy
control group in that study.
Gokhale et al found signiﬁcantly high NO levels in pa-
tients with active disease as compared to normal individuals
[10]. In that study there was signiﬁcant positive correlation
between the severity and duration of disease and NO levels
in patients with chronic plaque-type psoriasis.
In our study all the patients had the PASI score above
15 before treatment. The baseline serum nitrite-nitrate lev-
els were signiﬁcantly higher than the levels in nonlesional
(PASI = 0) period. Serum nitrite and nitrate levels of the
control group were signiﬁcantly lower than those of the pso-
riatic patients during the inﬂammatory stage. These ﬁndings
suggest a possible role of NO in the pathogenesis of psoria-
sis during the inﬂammatory phase. The results of our study
are consistent with the ﬁndings of previous studies in which
NO and iNOS levels in the tissue samples were investigated
[11, 14, 18, 25, 29].
Thenitriteplasmalevelsinthecontrolgroupweresignif-
icantly lower than in the psoriasis patients both before and
after treatment in our study (p = 0.0004). The nitrate levels
after treatment were higher than the control group but the
diﬀerence was not statistically signiﬁcant (P>. 05). We sug-
gest that serum nitrate level may be an important indicator
for the lesional period. The ﬁnding of higher serum nitrite-
nitrate levels than the healthy controls supports the idea that
the inﬂammation in psoriasis does not descend the normal
levels in clinically healed psoriatic patients. This opinion is
supported by the results of studies in the literature showing
the microscopic inﬂammation in nonlesional tissue samples
[1, 8, 13, 14].
As far as we know there are only two studies exploring
the correlation between psoriasis severity and NO levels in
the literature. Orem et al showed a positive relation between
serum nitrite and PASI [12]. Gokhale et al found signiﬁcant
positive correlation between the severity of disease and NO
levels in patients with chronic plaque-type psoriasis [10].
But we found no correlation between serum nitrite-nitrate4 Mediators of Inﬂammation
levels and PASI in our study. Our results support the the-
ory that the serum nitrite-nitrate levels indicate the systemic
inﬂammation and establish a relation between NO and pso-
riasis activity that is possible in laboratory conditions. How-
ever, it seems that the nitrite-nitrate concentration is not a
biomarker of psoriasis severity according to our ﬁndings.
Methotrexate was thought to act primarily on the rapidly
dividing basal keratinocytes of the psoriatic lesion. The
group of Weinstein demonstrated that proliferating lym-
phoid cells in psoriatic lesions are over 1000 times more sen-
sitive to the cytotoxic eﬀects of Mtx than primary human
keratinocytes [30]. It also has been shown that Mtx exerts
anti-inﬂammatory eﬀects mediated through intracellular ac-
cumulation of 5-aminoimidazole-4-carboxyamide ribonu-
cleotide, thereby increasing the release of adenosine. Adeno-
sine exerts anti-inﬂammatory eﬀects mainly on neutrophils,
where an inhibition of adhesion and reactive oxygen inter-
mediate production has been demonstrated [31].
The basic studies exploring the eﬀect of Mtx on NO lev-
elsareinvitro.ThesestudiesemphasizethatMtxinhibitsNO
by means of constitutive and/or inducible NO synthases in-
hibition [32–35]. There are some studies suggesting that Mtx
decreases the NO levels in psoriasis [13] Although there is no
relation between the cumulative dosage and nitrite-nitrate
levelsinnoninﬂammatoryperiodinourstudy,nitrite-nitrate
levels after treatment were signiﬁcantly lower than the levels
before. This result may show that Mtx decreases NO levels
and makes an anti-inﬂammatory eﬀect independent of the
cumulative dosage. This ﬁnding is similar to other reports
in the literature [13, 35, 36]. We can suggest that immuno-
logical and inﬂammatory mechanisms are important in the
etiopathogenesisofpsoriasisandthatNOplaysaroleinboth
mechanisms. The results in our study are comparable with
the studies investigating the lesional psoriatic tissue iNOS
andNOlevels[9,11,14].Thisrelationship betweenpsoriasis
and NO may pave the way for novel therapeutic approaches
such as selective iNOS inhibitors in the management of this
diﬃcult disease.
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